Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosis.
Biomarkers, Tumor
/ blood
Child
Child, Preschool
Circulating Tumor DNA
/ blood
DNA Copy Number Variations
Female
Humans
Infant
Kidney Neoplasms
/ diagnosis
Male
Neoadjuvant Therapy
Nephrectomy
Retrospective Studies
Sensitivity and Specificity
Whole Genome Sequencing
/ methods
Wilms Tumor
/ diagnosis
Kidney tumors
Pediatrics
Renal tumors
Wilms’ tumors
cell-free DNA
circulating tumor DNA
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 01 2019
01 01 2019
Historique:
received:
11
12
2017
revised:
27
03
2018
accepted:
11
05
2018
pubmed:
21
6
2018
medline:
16
4
2019
entrez:
21
6
2018
Statut:
ppublish
Résumé
Circulating tumor DNA (ctDNA) is a powerful tool for the molecular characterization of cancer. The most frequent pediatric kidney tumors (KT) are Wilms' tumors (WT), but other diagnoses may occur. According to the SIOP strategy, in most countries pediatric KT have a presumptive diagnosis of WT if they are clinically and radiologically compatible. The histologic confirmation is established after post-chemotherapy nephrectomy. Thus, there is a risk for a small fraction of patients to receive neoadjuvant chemotherapy that is not adapted to the disease. The aim of this work is to perform molecular diagnosis of pediatric KT by tumor genetic characterization based on the analysis of ctDNA. We analyzed ctDNA extracted from plasma samples of 18 pediatric patients with KT by whole-exome sequencing and compared the results to their matched tumor and germline DNA. Copy number alterations (CNAs) and single nucleotide variations (SNVs) were analyzed. We were able to detect tumor cell specific genetic alterations-CNAs, SNVs or both-in ctDNA in all patients except in one (for whom the plasma sample was obtained long after nephrectomy). These results open the door to new applications for the study of ctDNA with regards to the molecular diagnosis of KT, with a possibility of its usefulness for adapting the treatment early after diagnosis, but also for disease monitoring and follow up.
Substances chimiques
Biomarkers, Tumor
0
Circulating Tumor DNA
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
68-79Informations de copyright
© 2018 UICC.